• Abstract submissions will be considered for lecture or poster presentation during 2027 Congress sessions taking place Jan. 21-23, 2027, at the Hyatt Regency New Orleans.
• Abstracts must be submitted online through the abstract submission portal by the Sept. 23 submission deadline. No faxed, emailed or mailed abstracts will be accepted.
• There is no fee to submit an abstract.
• Authors do not have to be a member of the sponsoring organizations to submit an abstract.
• The submitter does not have to be the primary author or presenter.
• Submissions from international attendees and trainees are welcome and encouraged.

• Abstracts containing basic, clinical, or translational research findings in the field of IBD may be submitted.
• Abstracts that have been submitted to or presented at other national or international meetings may be submitted provided that prior presentation and/or submission to other meetings is declared during the Congress submission process.
• Abstracts that have been previously published as an article or full paper at the Sept. 23 submission deadline will not be considered for presentation and should not be submitted.
• Contact info@crohnscolitiscongress.org if you have any questions about abstract eligibility.

• Presenting authors of abstracts accepted for presentation are required to register for and attend the Crohn’s & Colitis Congress to present their abstract in person at the date and time specified in their acceptance invitation.
  • Virtual presentations (e.g., pre-recorded videos or live streams) will not be permitted.
  • View registration rates and discount deadlines.
• Abstract acceptance notifications will be sent to presenting authors on Tuesday, Nov. 10, 2026.
• The deadline to accept an invitation to present an abstract is 5 p.m. EST on Wednesday, Nov. 18, 2026. Failure to accept the invitation to present by the deadline will result in the automatic withdrawal of the abstract from the Congress program.
• Requests to change the presenting author of an abstract must be made in writing to info@crohnscolitiscongress.org.
  • Requests will be considered provided that the new presenter was listed as an author on the abstract at the time of submission. Only authors listed in the author string as of the Sept. 23 submission deadline are eligible to present an abstract at the Congress.
  • Requests to change presenters are subject to Congress administration approval pending the submission and receipt of financial disclosure and mitigation of any financial conflicts (if needed).

• The Congress financial disclosure site will open on Nov. 10, 2026.
  • Presenters of abstracts selected for poster presentation are not asked to submit financial disclosure for the Congress.
  • Presenting authors of abstracts selected for lecture presentation are required to disclose relationships with ineligible companies held over the past 24 months or indicate that no relationships exist. Presenters with relationships must indicate the name of the ineligible company and also the type of relationship held (e.g., owner, research grant, shareholder, employee, board member, consultant, etc.).
• Presenters of abstracts selected for lecture presentation will receive a link to the Congress financial disclosure site in the Nov. 10 abstract acceptance message.
• Lecture presenter disclosures must be submitted by 5 p.m. EST on Wednesday, Nov. 18, 2026. Please note this is the same deadline to accept the invitation to present an abstract at the Congress.
• Lecture abstracts missing presenter disclosures at the Nov. 18 deadline may be withdrawn from the Congress program.
• Lecture presenters will be granted conditional approval to participate in the Congress pending their completion of the disclosure form by the Nov. 18 deadline and subsequent mitigation of any relevant financial relationships.
  • If a financial conflict cannot be mitigated, Congress administration reserves the right to reschedule the abstract for poster presentation or withdraw the abstract to preserve attendees’ ability to claim CME for the meeting.

When submitting an abstract, authors must select one of the following categories that aligns with their science:

Clinical Science Submission Categories

• Adverse Events Related to Therapy
• Clinical Trials in Humans
• Comparative Effectiveness Studies
• Diagnostics in IBD
• Disease Activity Assessment and Monitoring
• Disease Complications
• Epidemiology, Environmental Determinants, Natural History, and Longitudinal Outcomes
• Health Care Quality, Delivery, and Policy
• Health Disparities
• IBD in Special Populations: Conception, Adolescence, and Older Adults
• Nutrition and IBD
• Pediatric IBD: Clinical and Translational Studies
• Quality of Life and Psychosocial Outcomes
• Uncontrolled Therapeutic Observations: Biologics
• Uncontrolled Therapeutic Observations: Non-Biologics
• Uncontrolled Therapeutic Observations: Non-Medical Treatment

Basic Science Submission Categories

• Animal Models of IBD: Pre-Clinical Treatment of Intestinal Inflammation
• Cytokines, Signaling and Receptors
• Genetics, Epigenetics, and Gene Function
• Intestinal Inflammation: Immune Cells
• Intestinal Inflammation: Non-Immune Cells, Injury, Repair, Fibrosis, and GI Cancers
• Microbiome Role in Intestinal Inflammation
• Mucosal Innate Function, Host Defense
• Omics for Diagnosis, Disease Stratification, and Therapy Selection
• Role of the Gut Microbiome, Fungi, Viruses, Phages, and Pathogens in Immune and Inflammatory Diseases
• Translational Application of Intestinal Stem Cells and Organoid Models

Authors can choose one topic only for each abstract submitted. If an abstract fits into more than one submission category, the submitter should choose the most appropriate one, as abstracts may be submitted only one time to a single category.

• Abstract titles may not exceed 255 characters, including spaces. Please refrain from using commercial names, institution names, non-standard abbreviations or author names in the abstract title.
• All abstract titles must be capitalized. The use of superscript, subscript and special characters in abstract titles is permitted.
• There is a limit of 2,900 characters, including spaces, for the abstract text. Information included in images submitted as part of the abstract does not count toward this limit.
• Abbreviations may be used if standard or if spelled out and defined at the first use (put in parentheses immediately after the first mention of a term or phrase). Compounds should be mentioned with the generic name, in lower cases.
• Authors are not required to use headings in their abstracts. If used, however, headings will count toward the 2900 character limit.
• Drug products mentioned in abstracts should be identified by their nonproprietary (i.e., generic) names only.
• Authors may submit up to two images per abstract. Images are not required.
  • Images will only be accepted in .bmp, .gif, .jpg., .png, or .tif file types. PDFs will not be accepted.
  • Images may not exceed 2 GB in size.
  • For assistance taking a screen shot of a Word, Excel or PowerPoint table and saving as an image, follow these instructions on taking a screen shot using Windows or using a Mac.
  • Please format your images appropriately, as images will be published as submitted if accepted for presentation. Be sure to remove any large white borders from images. Large images may be scaled for publication.

Submitted abstracts may be edited any time prior to the Sept. 23 submission deadline. To edit an abstract, the submitting author should log into the submission site and make the needed changes under the appropriate tasks at the submission site. Edited abstracts must then be saved and resubmitted by the submission deadline.

Submitted abstracts are noted at the submission site by a “complete” abstract status. Abstracts listed as “active” or “withdrawn” at the Sept. 23 deadline will not be reviewed or considered for presentation.

No edits to abstracts will be accepted after the submission deadline of 9 p.m. EST on Wednesday, Sept. 23.

• The deadline to submit an abstract for consideration for the 2027 meeting is 9 p.m. EDT on Wednesday, Sept. 23, 2026. Absolutely no changes to abstracts or author strings will be permitted after this deadline.
• The submitter certifies that they have the right to submit the abstract and that the data included in the abstract submission and/or presented at the Crohn’s & Colitis Congress is truthful, original, unduplicated, and without fraud or fabrication.
• The submitter certifies all authors listed in the submission are investigators with substantial involvement in the study presented in the abstract.
• By submitting an abstract, the submitting author confirms that he or she has permission from all co-authors to include their names in the submission and that all co-authors are aware of and agree to the content of the abstract and support the data contained therein. Submitting authors may, upon request by Congress administration, be asked to provide proof that all authors have given permission for the submission of the abstract and agree on its content.
• The submitter accepts responsibility for the accuracy of the original data and scientific content of the submitted abstract. Please proofread the abstract carefully prior to submission, as edits to an abstract or author string will not be permitted after the Sept. 23 submission deadline.
• The submitter confirms that the submitted abstract has not been previously published as an article or full paper as of the submission deadline.
• The submitter confirms that the abstract has not been submitted to more than one category or submitted by a co-author.
• The submitter confirms that copyright permissions for all third-party material (including and without limitation textual extracts or illustrations, photographs, maps, diagrams and tables) have been obtained.
• U.S. Government employee authors: The corresponding author warrants that the work was authored by employees of the U.S. government as part of their official duties and therefore may be published and reproduced without restriction.
• Abstracts that include clinical trial data should follow the CONSORT statement.
• Any human experimentation conducted conforms with the principles of the Declaration of Helsinki of the  World Medical Association, and meets all the requirements governing informed consent of the country in which the research was performed.
• Any animal studies should conform with the October 2014 revision of The Guiding Principles in the Care and Use of Vertebrate Animals in Research and Training by the American Physiological Society
• By submitting an abstract, the submitter accepts responsibility as the contact person for all correspondence about the abstract and will inform co-authors about its status. Only submitters and presenters will receive email from the Congress regarding abstract submission; co-authors will not receive email correspondence from the Congress regarding abstract acceptance status.
• Abstract acceptance notifications will be sent to presenting authors on Nov. 10, 2026.
  • Presenting authors must affirmatively accept their invitation to present by 5 p.m. EST on Nov. 18, 2026.
  • If an invitation is declined, the abstract will be removed from the Congress program.
  • Failure to respond to an invitation to present will result in removal of the abstract from the Congress program.
• Presenters of abstracts selected for lecture presentation are required to submit financial disclosure by 5 p.m. EST on Nov. 18, 2026.
  • Lecture presenters must disclose all financial relationships with ineligible companies over the past 24 months or by indicating that no relationships exist.
  • Presenters will receive a link to the Congress financial disclosure site in their abstract acceptance email on Nov. 10, 2026.
  • Abstracts missing lecture presenter disclosure at the Nov. 18 deadline may be withdrawn from the program.
  • Lecture presenters will be granted conditional approval to participate in the Congress pending their completion of the disclosure form by the Nov. 18 deadline and subsequent mitigation of any relevant financial relationships. If a financial conflict cannot be mitigated, Congress administration reserves the right to reschedule the abstract for poster presentation or withdraw the abstract to preserve attendees’ ability to claim CME for the meeting.
• Submission of an abstract constitutes a formal commitment by the presenting author to present the abstract in person in New Orleans in the session and at the time decided upon by the Congress Organizing Committee. Virtual presentations will not be permitted.
• Requests to change presenters are subject to the following policies:
  • Presenter changes must be made in writing to info@crohnscolitiscongress.org and are subject to approval by Congress administration pending receipt of financial disclosure and mitigation of any conflicts (if needed).
  • Abstracts may be presented only by authors listed in the author string at the Sept. 23 submission deadline.
• If an invitation to present an abstract has been accepted, failure to present it onsite in New Orleans could lead to rejection of abstracts submitted to future Crohn’s & Colitis Congress meetings.
• All presentations will be in English. Abstract presentations must be made by an author who speaks and understands English.
• Presenters are required to register to attend the Congress and must pay the applicable registration rate available at the time of registration.
  • Registrations cannot be transferred between abstract authors.
• Any expenses associated with the submission and presentation of an abstract are the sole responsibility of the authors.
• If selected for presentation, the copyright of the abstract is released to the Crohn’s & Colitis Foundation and AGA for publication in any and all Congress materials, including but not limited to online supplements to Gastroenterology and Inflammatory Bowel Diseases as well as inclusion at the Congress website, mobile app and/or any other Congress publications.
• Authors of abstracts accepted for presentation who participate in the meeting grant Congress administration royalty-free and unlimited use of their participation in any and all Congress program materials.

Prior to the Sept. 23 submission deadline, submitters may withdraw submitted abstracts at the submission site. After logging in, submitters should navigate to the abstract task list and then click on the abstract title. Next, using the “Select Status” dropdown, select “Withdrawn.” Finally, click “Save” to withdraw the abstract.

Beginning Sept. 24, 2026, Congress adminstration will withdraw abstracts upon written request to info@crohnscolitiscongress.org from the submitting author. Requests to withdraw abstracts should be made by 5 p.m. EST on Dec. 1, 2026. After this date, the Congress cannot guarantee that a withdrawn abstract will be excluded from publication.

All data presented at the Crohn’s & Colitis Congress is embargoed until 8 a.m. CST on the first day of the Congress, Thursday, Jan. 21, 2027.

Abstracts may be made available online to attendees in advance of the Congress for itinerary planning purposes. The embargo policy applies to all abstract data regardless of the date of publication in Congress resources.

1. Read the full abstract submission guidelines.
2. Log into the submission site and compose your abstract, ensuring that your abstract adheres to published character count limitations and formatting.
3. Upload up to two images (optional).
4. List all co-authors.
5. Review and proof abstract.
6. Finalize abstract and submit online by 9 p.m. EDT on Sept. 23, 2026.
7. Ensure the presenting author checks their email on Nov. 10, 2026, for an abstract decision email.